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Abstract: Several studies have indicated that radioimmunotherapy is an effective and clinically 
relevant complementary therapeutic approach for patients with B-cell non-Hodgkin’s lymphoma 
(NHL) and may convert partial to complete response when given as consolidation after induction 
chemotherapy. Yttrium-90(90Y)-ibritumomab tiuxetan (90Υ-ΙΤ, Zevalin®, Y2B8) has documented 
efficacy for both indolent and aggressive NHL. Patients considered eligible for 90Y-IT treatment 
should satisfy several screening criteria. A recently completed randomized study for patients 
with follicular lymphoma has demonstrated that 90Y-ibritumomab consolidation also produced 
a marked prolongation of the median time to progression from 13.5 to 37 months, while partial 
responders seem to derive relatively more benefit. Other published and ongoing studies explore 
a similar use for patients with aggressive lymphoma. Studies are comparing the use of   90Y-IT 
consolidation with the anti-CD20 antibody rituximab maintenance, which is also gaining accep-
tance. In conclusion, the documented benefit of radioimmunotherapy should be viewed in the 
context of the goals of treatment and the changing standards of care for lymphoma.
Keywords: radioimmunotherapy,  90Y-ibritumomab tiuxetan, follicular lymphoma, 
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Introduction
The therapeutic application of monoclonal antibodies has revolutionized the 
treatment of lymphoma.1 Although engagement and direct interaction with surface 
proteins appear to be of therapeutic value, antibodies also constitute excellent 
targeting systems, marking selected cells for the interaction with innate immune 
effector mechanisms, or by conjugation with moieties of therapeutic value which 
are thus locally delivered. Because radioimmunotherapy (RIT) has been shown to 
be sufficiently effective, the US Food and Drug Administration approved the first 
ever radioimmunoconjugate (RIC) for the treatment of a malignancy in February 
of 2002, when  90Y-ibritumomab tiuxetan (90Y-IT; Zevalin®; RIT Oncology) was 
licensed for the treatment of indolent or transformed, relapsed or refractory B-cell 
lymphoma. Soon therafter, a second anti-CD20 radioconjugate  131I tositumomab 
(Bexxar®; GlaxoSmithKline) was also approved.2,3 In Europe, 90Y-IT was subsequetly 
approved for the treatment of follicular lymphoma, relapsed or refractory after prior 
rituximab-containing treatment. Ibritumomab (IDEC-2B8) is the murine anti-CD20 
antibody developed by Biogen-IDEC (San Diego, CA, USA); its chimeric version, 
rituximab (Rituxan®; Genentech; Mabthera®; F. Hoffmann-La Roche Ltd), is also 
available and widely used. Tiuxetan connotes the linker used (MxDTPA) to conjugate 
90Y to the antibody.Cancer Management and Research 2009:2 132
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RIT offers several advantages over external beam 
irradiation. Normal tissues overlying the tumor mass are 
prevented from significant radiation exposure. Since the 
RIC is given intravenously, it provides systemic radiation 
treatment to known as well as unsuspected tumor cells. 
It should be noted that neither rituximab nor the RIC 
available or under development are truly tumor specific as 
they bind to a marker also present at the normal lymphocyte 
counterparts. However, mounting experience from trials 
and clinical practice suggests that prolonged normal B-cell 
depletion is not associated with significant sequelae.4 As a 
pure β emitter, 90Y seems to offer theoretical and practical 
advantages, mainly simple handling practices.5,6 The lack of 
γ component simplifies radioprotection during handling and 
administration of the RIC.
90Y-IT for the treatment  
of lymphoma
During the registrational clinical trials, a meticulous and 
thorough dosimetry procedure was performed, largely 
using data derived from indium-111 (111In-IT) kinetics.7,8 
The purpose of dosimetry was to eliminate the possibility 
of excessive radiation exposure of vital organs. Based on 
favorable observations on kinetics and safety, the requirement 
of imaging has been eliminated in most countries.9
Patients considered eligible for 90Y-IT treatment should 
satisfy several screening criteria, including having less than 
25% involvement of the bone marrow by disease determined 
by adequate core biopsy, absence of myelodysplasia, and 
satisfactory blood counts. In the phase I/II study, it became 
apparent that the major toxicity was reversible myelosup-
pression with median absolute neutrophil count (ANC) 
1100/µL and median nadir thrombocytopenia of 49,500/µL.10 
The extent of bone marrow involvement by lymphoma and 
the pre-treatment platelet counts correlate with the risk of 
myelosuppression. The remainder of the toxicity was mostly 
associated with the infusion of rituximab, with the possible 
exception of mild fatigue and mild nausea.
Studies of RIT as singe agent indicate that the expected 
response rate for patients fulfilling the above criteria with 
relapsed or refractory indolent or transformed B-cell NHL 
is 74% to 80% and duration of response is approximately 
1 year.4,11–13 Particularly longer remissions for several years 
were observed in subsets of patients.4 Importantly, in the 
211 patients of the registrational studies, there was no 
difference in toxicity and efficacy of the treatment among 
the 113 patients less than 60 years old, the 58 patients 
of the age group between 60 and 70 and the 40 patients 
over 70.14 For aggressive B-cell lymphoma, the activity of 
90Y-IT has been documented in the phase I/II study10 and it 
was confirmed in a multicenter prospective phase II study 
involving 102 evaluable patients;15 in the latter, an overall 
44% response rate with 27% complete response CR) rate 
was observed. The results were more favorable in rituximab 
naïve patients. In relapsed mantle cell lymphomas the activity 
of   90Y-IT has been reported in the range of 30% to 40% but 
responses usually last a few months.16
Rationale for consolidation use  
of RIT
There are many reasons to consider the delivery of 
radiotherapy immediately after a course of chemotherapy, 
ie, as commonly referred to, as consolidation treatment. 
It is conceivable that induction chemotherapy may “prime” 
patients for an enhanced RIT effect. In multivariate analysis 
of 203 patients involved in the 90Y-IT registrational studies, 
a factor that predicted for better response was tumor bulk;16 
patients with nodal masses more than 5 cm had a 68% 
response rate, as opposed to 90% for patients with smaller 
tumors (P  0.001). Thus, cytoreduction achieved by 
chemotherapy may render patients more amenable to RIT. 
In addition, chemotherapy treatment usually results in ame-
lioration of bone marrow disease, so that the likelihood of 
considerable bone marrow involvement exceeding 25% is 
extremely low. This may translate in reduced bone marrow 
exposure to irradiation. Furthermore, the impact of RIT on 
measurable residual disease could be quantified, ie, one 
could know how many partial responses could be converted 
to complete ones.
Retrospective meta-analysis of the registrational trials 
indicate a considerably better outcome in patients treated 
with radiotherapy early in their disease course;17 for instance, 
in patients with follicular lymphoma receiving  90Y-IT as 
second line treatment, the complete and overall response rate 
were 51% and 89% respectively. The complete response (CR) 
rate and time to progression (TTP) were statistically better 
compared to the group of patients with more prior treatments 
(P  0.05). Patients who achieved a CR had a median 2-year 
TTP. Such data suggest that it may be preferable to move up 
90Y-IT treatment in the sequence of therapy for lymphoma, 
in order to take advantage of the high likelihood of achieving 
a CR, which confers a longer TTP. In fact, a response rate of 
100% has been reported after first-line use of RIT in patients 
with follicular lymphoma.18 Late toxicity and particularly 
myelodysplasia seems not to be an issue, so that subsequent 
treatments upon relapse are possible.19,20Cancer Management and Research 2009:2 133
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All the above observations support the use of RIT as 
a practical and convenient consolidation treatment after 
induction chemotherapy as it may be associated with 
increased efficacy and lack of long-term toxicity.
Nevertheless, there are certain theoretical concerns for 
indiscrete consolidation treatment with RIT. The ratio of 
beneficial radiation vs radiation deposited to surrounding 
tissue depends on the size of the lymphomatous mass and 
the path length of the radioisotope used. Since most of the 
radiation energy is delivered within a sphere with a radius of 
a few millimeters, if one conceptualizes residual disease as a 
dispersion of single cells, most of the radiation emitted by the 
lymphoma-attached radioconjugate would be wasted. On the 
other hand, the definition of complete response is a convention, 
which almost certainly includes patients with small lympho-
matous aggregates in “normal size” lymph nodes of less than 
1.5 cm. Thus, complete responders may still derive benefit 
from the crossfire effect. This is more valid if the response 
to preceding chemotherapy was not complete; in such cases, 
RIT may be an ideal agent to treat the remaining involved 
nodes. Chemotherapy-resistant lymphoma cells may still be 
susceptible to radiation as significant activity of RIT in patients 
with chemotherapy refractoriness has been reported.12,21 
Another concern about consolidation use is whether a bone 
marrow in the process of recovering and regenerating from 
the effects of recent myelotoxic chemotherapy can sustain 
safely the effect of RIT. Completed studies seem to indicate 
that an interval period of 4 to 6 weeks post-chemotherapy 
is sufficient for safe administration of RIT. The inclusion 
of the anti-CD20 antibody in the induction chemotherapy 
does not eliminate the benefit of anti-CD20-based RIT. The 
interaction of the antibody with its target should be viewed as 
a dynamic process of equilibrium with constant detachment 
of antibody molecules and replacement by others. In any case, 
RIT is known to be active even in the presence of measurable 
rituximab levels, as shown in the study in rituximab-refractory 
follicular B-cell lymphoma patients.10
Consolidation studies
indolent NHL
The proof of principle of radioimmunotherapy consolidation 
was first demonstrated by the Southwest Oncology Group 
(SWOG) phase II study in 90 patients with untreated follicular 
Β-cell non-Hodgkin’s lymphoma.22 After an initial full 
course CHOP (cyclophosphamide, doxorubicin, vincristin, 
prednisolone) chemotherapy, responding patients received 
the radioconjugated anti-CD20 antibody  131I-tositumomab 
(131I-T) as consolidation. The mean time between the end 
of chemotherapy and the treatment with RIT was 35 days. 
RIT was well tolerated without excessive myelotoxicity, 
and 57% of the patients achieving less than a CR after 
chemotherapy, improved their remission with RIT. Thus 
the overall response rate was 90% including 67% complete 
responses, and the 2-year progression-free survival was esti-
mated at 81%. The same radioimmunoconjugate was tested 
after an abbreviated 3-cycle course of fludarabine first-line 
treatment.23 The sequence induced a complete response in 
83% of the 35 evaluable patients. Grade 4 neutropenia or 
thrombocytopenia was noted in 34% and 29% respectively.
A number of studies have subsequently examined the 
role of  90Y-IT as consolidation treatment in B-cell NHL. 
In the Sarah Cannon Cancer Center, an abbreviated 3-cycle 
regimen of CHOP–rituximab or CVP (cyclophosphamide, 
vincristine, prednisone)–rituximab was followed by 90Y-IT, 
which is thus used as a chemotherapy sparing agent.24 90Y-IT 
was given 5 to 7 weeks after the last chemotherapy cycle. All 
of the 22 reported patients resonded; there were 13 partial 
responders to chemotherapy, 10 of whom achieved a CR after 
90Y-IT, for an overall CR rate of 86%. Responses were long-
lasting. Limited grade 4 neutropenia or thrombocytopenia 
was seen (18% and 0% respectively). This study preliminarily 
addressed the relevant question of whether 90Y-IT consolida-
tion would perform well after rituximab-containing induction 
regimens. Further evidence is provided by a phase 2 study 
of 3-cycle rituximab-CHOP induction chemotherapy given 
to patients with symptomatic or bulky untreated follicular 
NHL followed by 90Y-IT consolidation supplemented by 4 
additional rituximab infusions.25 In that study involving 60 
patients, the addition of RIT consolidation nearly doubled 
the PET-confirmed CR rate achieved by rituximab–CHOP, 
from 46% to 89%. After a median follow up of 19 months, 
10 patients relapsed, an outcome better than expected.
Results of  90Y-IT consolidation following alternative 
chemotherapy (fludarabine–mitoxantrone combination) are 
suggestive of similar efficacy. Applying 90Y-IT consolidation 
to a group of 61 patients with follicular NHL after treatment 
with 6 cycles of oral fludarabine and mitoxantrone resulted 
in a 96% overall response rate.26 Radioimmunotherapy 
converted 12 of the observed partial responses to complete 
ones. With a median observation time of 30 months, the 
3-year actuarial progression-free and overall survival was 
76% and 100% respectively. Grade 3 or 4 hematologic 
toxicity was noted in 36 of 57 evaluable patients, and blood 
or platelet transfusions were often required. The feasibility 
of the same strategy with analogous results has been 
reported by the same group in patients with non-follicular Cancer Management and Research 2009:2 134
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indolent B-cell lymphoma.27 Although direct comparisons 
are not possible, it is likely that the type of regimen as well 
as the number of chemotherapy cycles may have resulted 
in increased hematologic toxicity compared to the Sarah 
Cannon study.
Phase 3 study of 90Y-iT consolidation
The remarkable and consistent observation across these 
phase 2 studies of the capacity of 90Y-IT to further enhance 
the response obtained by chemotherapy led the design of a 
multicenter phase 3 study known with the acronym FIT.28 
In order to overcome difference of opinions among various 
lymphoma specialists regarding the optimal first line regimen, 
the study randomized 409 patients with stage III and IV 
follicular NHL after they had achieved a response to a first-
line induction regimen of the choice of the site investigators. 
Patients were assigned to either receive 90Y-IT consolidation 
or just be observed, with progression-free survival being 
the primary end-point. Nearly all patients had stage 3 or 4 
disease and were roughly equally divided between partial and 
complete responders. The majority of patients had received 
alkylator-based regimens, predominately CHOP. Fludarabine 
combination was given to 5.4% and 15% had been exposed 
to rituximab.
The administration of 90Y-IT, as expected, increased the 
complete response rate, which at the end of the treatment 
was 87% in the radioimmunotherapy group and 53% in the 
control group. This resulted in a remarkable prolongation of 
the progression-free survival from a median of 13.5 months in 
the control group to 37 months (P  0.0001). In the subset of 
patients with partial response who entered the randomization, 
the difference was even more pronounced (6.3 months vs 29.7 
months, P  0.0001). The benefit in complete response and 
prolongation of the time to treatment failure was seen in all 
treatment groups, regardless of the intensity of the induction 
regimen. However, because of the small size of the subset 
of patients who had received rituximab-based treatment, the 
difference in this group did not reach statistical significance 
(CR rate of 71% vs 93%, overlapping 95% confidence 
intervals). Overall survival data are premature, but given 
the likelihood of crossover and multiple lines of subsequent 
treatments, it is doubtful that an improvent in overall survival 
can be demonstrated from this study. Nevertheless, updated 
results confirm the long term safety of RIT consolidation, as 
well as the feasibility of subsequent treatments, as expected.29 
The rates of grade 3–4 thrombocytopenia, neutropenia 
and anemia in the  90Y-IT group was 61%, 67% and 3% 
respectively. Despite that, grade 4 infections were observed 
in only 8% of the patients. Platelet transfusions were given at 
the discretion of the investigators to 42 patients (20%), and 
leukocyte growth factor support to 36 patients.
This  randomized  study  confirmed  the  value  of 
radioimmunotherapy given as supplement to chemotherapy 
and has led to the approval of 90Y-IT as consolidation after 
induction chemotherapy for follicular lymphoma. However 
this study leaves several unanswered questions. For instance, 
it leaves unsettled the question of whether reserving radioim-
munotherapy delivery as treatment upon progression would 
benefit the patient at the same extent. On the other hand it is 
possible that the temporal proximity of radioimmunotherapy 
to lymphoma cells recently exposed to chemotherapy may 
make them more susceptible to apoptosis and thus enhance 
cell killing conferred by irradiation (chemosensitization). 
Another somewhat unclear issue is the exact magnitude of 
benefit from 90Y-IT consolidation after rituximab-containing 
induction chemotherapy. Along those lines, as rituximab 
maintenance is gaining acceptance, a subsequent multicenter 
randomized study is underway, comparing RIT consolida-
tion to rituximab mainenance, or assessing the benefit of the 
addition of 90Y-IT consolidation on chemoimmunotherapy 
followed by rituximab maintenance backbone. It is note-
worthy that the magnitude of the benefit of 90Y-IT consoli-
dation seems to be in the same range of that conferred by 
rituximab maintenance; for the sake of comparison, adding 
4 weekly rituximab infusions every 6 months for 2 years 
after CVP–rituximab induction chemotherapy for follicular 
lymphoma increased the 3-year disease-free survival from 
33% to 68%.30 Notwithstanding the above reservations, 
the FIT trial has demonstrated beyond doubt the value of 
radioimmunotherapy consolidation in the first-line treatment 
of patients with follicular indolent lymphoma.
90Y-iT consolidation use  
for aggressive NHL
The documentation of considerable activity of  90Y-IT in 
patients with relapsed or refractory diffuse large B-cell 
lymphoma10,15 as well as the desire for further improvement 
of the overall survival in such group of patients led to the 
initiation of consolidation studies, most of which are still 
in progress. A phase 2 study describing the administra-
tion of   90Y-IT as consolidation after full course of CHOP 
chemotherapy in patients over the age of 60 has been published 
and documents again the feasibility of this strategy, result-
ing in a 100% overall response rate and an actuarial 2-year 
disease-free survival of 2 years.31 Ongoing studies aim at 
reproducing these results. Consolidation with 90Y-IT has also Cancer Management and Research 2009:2 135
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been studied in patients with stage I-II diffuse large B-cell 
lymphoma of relatively high risk who were treated with CHOP 
for 3 cycles and involved field irradiation; 90Y-IT consolidation 
was added to this standard regimen.32 The 2-year disease-free 
survival was estimated to be 91%, an encouraging outcome. 
A randomized study assessing the role of Zevalin® as con-
solidation after completion of full course R-CHOP in patients 
with aggressive lymphoma is underway. The goal of treatment 
of patients with aggressive lymphoma is to produce cures and, 
albeit somewhat ambitiously, such studies intend to explore 
a possible increase in overall survival.
In mantle cell lymphoma, the sequence CHOP-rituximab 
followed by 90Y-IT consolidation has been tested as first-line 
treatment in 56 patients by the Eastern Cooperative Oncology 
Group (ECOG).33 After 4 cycles of R-CHOP, the overall 
response rate and the complete response rate were 72% and 
14% respectively. Similar to other consolidation studies, after 
administration of 90Y-IT the responses increased respectively 
to 84% and 45%. A similar approach employing the com-
bination of fludarabine, mitoxantrone, cyclophosphamide 
and rituximab (FCM-R) as induction regimen followed by 
90Y-IT consolidation was reported to induce CR in 19 out of 
20 patients with untreated mantle cell lymphoma and with 
an excellent so far freedom from progression.34 However, for 
relapsed mantle cell lymphoma, the same regimen was less 
efficacious; it induced a 40% CR and a TTP of 7 months in 
a small group of patients. Similar strategies are pursued by 
other groups. It emerges from the above studies, that 90Y-IT 
may be particularly helpful in the treatment of mantle cell 
lymphoma as consolidation after first-line chemotherapy, but 
its usefulness in relapsed disease, either as monotherapy or 
as consolidation is limited.
Conclusion
The clinical evidence discussed above supports the role 
of  90Y-IT as a useful consolidation agent after induction 
chemotherapy for lymphoma. In particular, the randomized 
phase 3 study (FIT) has demonstrated a remarkable prolon-
gation of time to disease progression conferred by 90Y-IT 
consolidation after induction chemotherapy in patients with 
follicular non-Hodgkin’s B-cell lymphoma and therefore has 
produced an unequivocal clinical paradigm. This use can be 
supported by the feasibility of subsequent chemotherapy 
treatments, the apparent lack of long-term toxicity and the 
low infectious risk. Such application should be considered 
in patients with follicular lymphoma when prolongation of 
remission is desired. This concept is particularly useful for 
patients with less than complete response to chemotherapy. 
The clinical merits of such consolidation use should be 
carefully weighed in each individual patient case taking into 
account the goals of treatment and the willingness to incur 
the risk of radioimmunotherapy-related toxicity. Whether the 
pre-emptive treatment with RIT of the residual disease may 
be more beneficial in terms of overall survival compared to 
reserving RIT for the inevitable progression of the indolent 
lymphoma will remain an important question to be answered 
in the subsequent years. If the hypothesis of “temporal 
synergy”, as hypothesized above, is true, then consolidation 
use ought to be more beneficial than RIT treatment upon 
progression.
The conclusions of the FIT study allow the incorporation 
of RIT consolidation in an overall treatment strategy for 
follicular lymphoma, that may also include protracted 
maintenance such as ritiximab long-term use. Accord-
ingly, it is conceivable that a successful future strategy for 
follicular NHL may include an induction chemotherapy 
regimen followed by 90Y-IT consolidation, to be followed by 
rituximab maintenance; this remains an intriguing research 
question for the future. Presently, radioimmunotherapy 
consolidation with  90Y-IT represents an attractive and 
relatively brief consolidation treatment option, associated 
with prolongation of remission, a particularly desired 
outcome for most patients with follicular lymphoma. 
Ongoing randomized studies may further elucidate its role 
as consolidation agent for aggressive lymphoma and within 
the framework of an ever-changing lymphoma standard 
of care.
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